Polar Capital Holdings Plc

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Arcutis Biotherapeutics, Inc. 13G ARQT · 03969K108	ARQT	03969K108	5.3%	6,606,945	13G	8/14/2026 Event 6/30/2026
Polar Capital Holdings Plc			5.3%	6,606,945
Polar Capital LLP			5.3%	6,606,945
Verastem, Inc. 13G/A Amendment 1 VSTM · 92337C203	VSTM	92337C203	4.8%	3,700,000	13G/A Amendment 1	7/8/2026 Event 3/31/2026
Polar Capital Holdings Plc			4.8%	3,700,000
Polar Capital LLP			4.8%	3,700,000
Polar Capital Funds PLC - Biotechnology Fund			4.8%	3,700,000
Enliven Therapeutics, Inc. 13G/A Amendment 3 ELVN · 29337E102	ELVN	29337E102	8.5%	5,056,807	13G/A Amendment 3	6/22/2026 Event 3/31/2026
Polar Capital Holdings Plc			8.5%	5,056,807
Polar Capital LLP			8.5%	5,056,807
Polar Capital Funds PLC - Biotechnology Fund			8.5%	5,056,807
Enliven Therapeutics, Inc. 13G/A Amendment 2 ELVN · 29337E102	ELVN	29337E102	8.5%	5,056,807	13G/A Amendment 2	5/15/2026 Event 3/31/2026
Polar Capital Holdings Plc			8.5%	5,056,807
Polar Capital LLP			8.5%	5,056,807
Polar Capital Funds PLC - Biotechnology Fund			8.5%	5,056,807
Enliven Therapeutics, Inc. 13G/A Amendment 1 ELVN · 29337E102	ELVN	29337E102	8.5%	59,800,406	13G/A Amendment 1	5/15/2026 Event 3/31/2026
Polar Capital Holdings Plc			8.5%	59,800,406
Polar Capital LLP			8.5%	59,800,406
Polar Capital Funds PLC - Biotechnology Fund			8.5%	59,800,406
Verastem, Inc. 13G VSTM · 92337C203	VSTM	92337C203	5.1%	3,398,898.71	13G	1/5/2026 Event 12/31/2025
Polar Capital Holdings Plc			5.1%	3,398,898.71
Polar Capital LLP			5.1%	3,398,898.71
Polar Capital Funds PLC - Biotechnology Fund			5.1%	3,398,898.71
Hagerty, Inc. 13G/A Amendment 2 HGTY · 405166109	HGTY	405166109	5.9%	5,306,865	13G/A Amendment 2	9/4/2025 Event 6/30/2025
Polar Capital Holdings Plc			5.9%	5,306,865
Polar Capital LLP			5.9%	5,306,865
Polar Capital Funds PLC - Biotechnology Fund			5.9%	5,306,865
Hagerty, Inc. 13G/A Amendment 1 HGTY · 405166109	HGTY	405166109	0%	0	13G/A Amendment 1	8/14/2025 Event 6/30/2025
Polar Capital Holdings Plc			0%	0
Polar Capital LLP			0%	0
Polar Capital Funds PLC - Biotechnology Fund			0%	0
Arcutis Biotherapeutics, Inc. 13G/A Amendment 3 ARQT · 03969K108	ARQT	03969K108	4.2%	5,006,472	13G/A Amendment 3	8/14/2025 Event 6/30/2025
Polar Capital Holdings Plc			4.2%	5,006,472
Polar Capital LLP			4.2%	5,006,472
Polar Capital Funds PLC - Biotechnology Fund			4.2%	5,006,472
Enliven Therapeutics, Inc. 13G ELVN · 29337E102	ELVN	29337E102	5.2% Checked 5% or less	2,536,881	13G	8/14/2025 Event 6/30/2025
Polar Capital Holdings Plc			5.2%	2,536,881
Polar Capital LLP			5.2%	2,536,881
Polar Capital Funds PLC - Biotechnology Fund			5.2%	2,536,881
NeuroPace Inc 13G NPCE · 641288105	NPCE	641288105	9.1%	2,972,003	13G	5/15/2025 Event 3/31/2025
Polar Capital Holdings Plc			9.1%	2,972,003
Polar Capital LLP			9.1%	2,972,003
Arcutis Biotherapeutics, Inc. 13G/A Amendment 2 ARQT · 03969K108	ARQT	03969K108	5.7%	6,706,475	13G/A Amendment 2	5/15/2025 Event 3/31/2025
Polar Capital Holdings Plc			5.7%	6,706,475
Polar Capital LLP			5.7%	6,706,475
Polar Capital Funds PLC - Biotechnology Fund			5.1%	6,000,000
Vtex 13G/A Amendment 1 VTEX · G9470A102	VTEX	G9470A102	2.8%	5,232,020	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Polar Capital Holdings Plc			2.8%	5,232,020
Polar Capital LLP			2.8%	5,232,020
Polar Capital Funds PLC - Biotechnology Fund			2.8%	5,232,020
Enliven Therapeutics, Inc. 13G/A Amendment 1 ELVN · 29337E102	ELVN	29337E102	4.9%	2,389,668	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Polar Capital Holdings Plc			4.9%	2,389,668
Polar Capital LLP			4.9%	2,389,668
Polar Capital Funds PLC - Biotechnology Fund			4.9%	2,389,668